Form 4: TriSalus Chief of Research Sells Shares for Tax Obligations

TriSalus Life Sciences' Chief of Research, Bryan F. Cox, sold a total of 3,184 common shares across three transactions in March 2026 to cover tax withholding obligations related to vested restricted stock units.

Summary

• Bryan F. Cox, Chief of Research at TriSalus Life Sciences, Inc. (TLSI), reported sales of common stock.
• The sales occurred on March 11, 2026, March 12, 2026, and March 16, 2026.
• A total of 3,184 shares were sold across these three transactions.
• The sales were non-discretionary, executed solely to satisfy tax withholding obligations arising from the vesting of previously granted restricted stock units.
• The shares were sold at prices ranging from $4.09 to $4.13 per share.
• Following these transactions, Mr. Cox beneficially owns 163,415 shares of TriSalus Life Sciences common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sales were non-discretionary and solely for tax purposes, not reflecting a change in the insider's investment sentiment.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

StockSavvy.ai notes that routine insider sales for tax purposes, as reported in Form 4 filings, are common and generally do not indicate a change in management's confidence in the company's prospects. These transactions are often pre-scheduled under Rule 10b5-1 plans.

Stakeholder Impact

• Shareholders: Minimal impact, as the sale is non-discretionary and for tax purposes, not signaling a change in company fundamentals or insider confidence.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Key Dates

Recommendation

This Form 4 filing details a non-discretionary sale of shares by an insider to cover tax obligations from RSU vesting. Such transactions are routine and do not typically signal a change in the company's fundamentals or the insider's confidence. Therefore, it provides no new information to warrant a change in investment recommendation.

Keywords

TriSalus Life Sciences, TLSI, Form 4, insider trading, stock sale, tax withholding, restricted stock units, RSU, Bryan F. Cox